LivaNova PLC: stock overview

LIVNNASDAQHealthcare · Electromedical & Electrotherapeutic Apparatus

Price

$91.92

November 17, 2026Market cap $5.0B

What Ploutos Investor adds for LivaNova

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 10 fiscal years, from 2016
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • Most of the reported profit is a tax credit, not money earned from customers. We leave out the P/E and the earnings growth, which would not compare with a company that paid tax.

In short

LivaNova had revenue of $1.5B over the last 12 months and net income of $196M, a net margin of 13.0%. Revenue grew by 8.2% a year on average over the last 5 years. It holds more cash than debt, by $264M. It pays no dividend.

From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 17, 2026.

Its SEC filings
Market cap
$5.0B
54.69M shares
P/E
–
Revenue, 12 months
$1.5B
+8.2% a year over 5 years
Net margin
13.0%
2025: -17.5%, above 27% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

2023–2025 fiscal years

+9.7% a year over 2 years

  • 202510-K
    Revenue$1.4B
  • 202410-K
    Revenue$1.3B
  • 202310-K
    Revenue$1.2B

Fiscal years in figures

LIVN's revenue, profit, cash flow and dividend with each year-end price, from 2016 to 2022, 7 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $2.8B
$5.0B
Enterprise value 
$4.8B
P/E 
–
EV / EBIT 
29.4
EV / Revenue 
3.2
P/B 3-year median: 2.2
3.7
FCF yield 3-year median: 5.1%
2.6%
Earnings yield 3-year median: 0.6%
–

Profitability

Gross margin 
67.8%
Operating margin 
10.8%
Net margin 3-year median: 1.5%
13.0%
ROIC 
8.0%
ROIC, 5-year average 
1.8%
ROE 
15.7%

Growth

Revenue, yearly change 
+10.7%
EPS, yearly change 
–
FCF, yearly change 
+27.5%
Revenue, average a year 
+8.2%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$563M
Total debt 
$357M
Of which operating leases 
$58M
Net cash 
$264M
Net debt / EBITDA 
-1.4x
Interest cover 
5.1x
Current ratio 
1.46

Balance sheet of September 30, 2026.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
–
Total returned 
0.00%
Shares, yearly change 
+0.6%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 38).

Gross margin

67.7%

Above 74% of the 161 companies in its industry, and 84% of all.

Operating margin

14.4%

Above 72% of the 186 companies in its industry, and 74% of all.

Net margin

-17.5%

Above 27% of the 189 companies in its industry, and 14% of all.

ROE

-20.2%

Above 27% of the 174 companies in its industry, and 14% of all.

ROA

-9.3%

Above 31% of the 190 companies in its industry, and 15% of all.

Revenue growth

10.7%

Above 59% of the 186 companies in its industry, and 65% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
LivaNova PLC
Exchange
NASDAQ
Industry (SIC)
3845 · Electromedical & Electrotherapeutic Apparatus
Fiscal year ends
December 31
Latest annual report
December 31, 2025
Reporting currency
USD
Shares
54.69M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do LivaNova's filings show?

These are LivaNova's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about LIVN

Didn't find what you were looking for?

Ask us
What is LIVN's market cap?

LivaNova PLC's market cap is $5.0B, at a price of $91.92 on November 17, 2026 and 54.69M shares.

How much revenue does LIVN have?

LivaNova had revenue of $1.5B over the last 12 months. Over the last 5 years it changed by +8.2% a year on average.

Does LIVN pay a dividend?

No. LivaNova paid no regular dividend over the last 12 months.

Where do the figures come from?

From LivaNova PLC's SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.